Topotecan/Taxol in First-Line Small-Cell Lung Cancer: Where Is the Benefit?

Publisher： Karger

E-ISSN： 2296-5262|23|3|7-8

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.23, Iss.3, 2000-05, pp. : 7-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Topotecan in the First-Line Treatment of Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-05 ,pp. : 13-17

Karger

Access to resources Recommend Favorite

Status of Topotecan in Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-05 ,pp. : 1-1

Karger

Access to resources Recommend Favorite

Topotecan (Hycamtin®) in the Therapy of Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1999-01 ,pp. : 13-17

Karger

Access to resources Recommend Favorite

First-Line Therapy of Mutated Non-Small Cell Lung Cancer: An Update

By  

Oncology Research and Treatment, Vol. 35, Iss. 5, 2012-04 ,pp. : 293-299

Karger

Access to resources Recommend Favorite

Docetaxel as a Single Agent in First-Line Therapy of Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 6, 2004-11 ,pp. : 16-17

Karger

Access to resources Recommend Favorite